Dental Implant Planning for Cancer Survivors and Immunocompromised Patients

Cancer survivor and immunocompromised are broad labels, not dental implant diagnoses. One person may have completed treatment for a solid tumour and have no ongoing immune suppression. Another may be receiving chemotherapy, targeted therapy or immunotherapy. Another may have undergone a haematopoietic cell transplant, live with graft-versus-host disease, take immune-modifying medicines, have altered blood counts, or have received radiation involving jaw tissue. Those situations cannot share a universal implant timetable or eligibility statement.

This guide is general information, not personalised medical or dental advice. It does not publish blood-count thresholds, radiation cut-offs, drug holidays, antibiotic regimens or fixed waiting periods. Those decisions require the exact cancer diagnosis, treatment status, treatment modalities, dates, sites or fields, and medicines, plus current oral findings and input from the professionals responsible for oncology, haematology or transplant care.

WeCare is not the treating dental provider. WeCare's role is limited to enquiry and referral coordination and, if separately agreed, travel logistics only to the extent confirmed in writing. The named clinic and named clinician must own dental examination, diagnosis, consent, treatment, prescriptions, records, complaints and clinical aftercare. The patient's oncology, haematology or transplant team owns cancer status, treatment, immune recovery, blood interpretation and medical risk. A coordinator cannot clear a patient for implant surgery.

The word survivor can be personally meaningful, but it does not tell a dentist whether treatment is active, paused, completed or changing. The word immunocompromised is also not a single clinical state. Cause, severity, duration, current infection risk, blood and organ function, medicines, oral tissues and the planned surgical burden all matter. Good planning replaces labels with verified details.

Diagnosis and treatment status before implant planning

Begin with the exact diagnosis and current status. Record the cancer type, affected site, whether it is a solid or haematological malignancy, current disease status in the language used by the oncology team, and the named service responsible for follow-up. Do not ask the patient to convert an oncology letter into a dental suitability decision. The dentist should read relevant records and ask focused questions.

List every cancer-related treatment, not only chemotherapy. This may include surgery, systemic anti-cancer therapy, radiotherapy, haematopoietic cell transplantation, CAR T-cell therapy, targeted therapy, immunotherapy, endocrine therapy, antiresorptive treatment, antiangiogenic treatment, corticosteroids or other immune-modifying medicines. The list is not a prediction of risk. It tells the named clinician which professional guidance and specialist input may be relevant.

For systemic treatment, record generic medicine names where possible, start and completion information, cycle or phase status, recent changes, adverse effects, and the responsible prescriber. For transplant care, record the transplant type, current transplant-team follow-up, graft-versus-host disease status where relevant, immune-modifying medicines and any current precautions. For radiotherapy, obtain the treatment summary rather than relying on the phrase head and neck radiation.

The cancer treatment site matters. Radiotherapy outside the head and neck does not expose jaw tissue in the same way as a field involving the mandible or maxilla. Head and neck treatment still cannot be reduced to yes or no. The dental specialist may need radiation dose distribution and the location of the planned implant or other bone-impacting procedure.

Current status is more important than an elapsed-time slogan. Ask whether treatment is ongoing, planned to restart, recently changed, under surveillance, or complicated by infection, cytopenia, graft-versus-host disease, mucositis, dry mouth, poor intake, bleeding or another active issue. Ask whether the oncology team has provided written precautions for dental care.

Record other conditions and medicines. Anticoagulants, antiplatelets, antiresorptives, antiangiogenic agents, steroids and other treatments may change bleeding, infection, bone or wound considerations. Over-the-counter and herbal products belong in the history too. Do not stop, start, delay or change any cancer, immune, bone or other medicine because of a dental website or travel plan.

If information is missing, the output is not a clearance. It is a list of records and clinical questions needed before a decision. A provisional estimate should say that clearly.

Oncology, haematology and transplant-team ownership

The oncology, haematology or transplant team owns interpretation of cancer activity, treatment phase, immune status, blood counts, transplant recovery, graft-versus-host disease and treatment-related medical precautions. The dental clinician owns oral diagnosis, implant alternatives, procedural extent, oral infection management, dental prescribing, consent, surgery and dental aftercare. Neither should hand responsibility to a salesperson.

Communication should be specific. A dentist should describe the planned intervention: site, likely flap or bone involvement, anticipated grafting, number of surgical areas, anaesthesia or sedation, expected wound burden and available aftercare. The medical team can then comment on the current medical context and whether further coordination is needed. A vague request asking whether the patient is fit for dentistry is less useful.

For haematological malignancy, transplant or CAR T-cell therapy, the medical team may need to interpret blood, immune and treatment-phase information that a general dental practice cannot assess alone. The MASCC/ISOO clinical practice statement on dental evaluation before haematological cancer treatment emphasises coordination between dental and haemato-oncology teams, especially for invasive care and infection or bleeding risk.

The treating dental clinician must also decide whether the proposed setting and personal competence are appropriate. Some patients may need an oral medicine, special care, oral surgery, maxillofacial or hospital dental service. Referral is a safety decision, not a rejection. The rationale should be documented and explained.

Where a patient has several specialists, identify one accountable contact for each question. The transplant physician may address immune reconstitution, the radiation oncologist can supply dose distribution, the medical oncologist can clarify systemic treatment, and a haematologist can interpret haematological status. The dentist integrates only the information within dental competence.

Do not use a coordinator as the sole channel for medicine or laboratory instructions. With patient consent, professionals should exchange relevant records through an attributable, secure route. The patient should receive the final written plan and know which professional authored each instruction.

If clinicians disagree, elective treatment should pause while the disagreement is resolved. A flight date or deposit does not settle a clinical question.

Urgent dental care before elective implants

Implant placement is elective. Pain, swelling, dental infection, trauma, uncontrolled bleeding, mucosal ulceration, exposed bone or inability to eat may require urgent assessment, but urgent care may involve stabilisation rather than an implant. A patient who is currently receiving cancer treatment or is known to be immunocompromised should use the oncology team's emergency instructions and a local urgent dental or medical pathway.

NICE CG151 states that a person receiving anticancer treatment who becomes unwell may have suspected neutropenic sepsis and should be referred immediately for secondary or tertiary assessment. The patient should follow the alert thresholds and contact route given by their own oncology service. This guide does not substitute a universal temperature rule or advise self-treatment.

Call emergency services for severe swelling affecting breathing or swallowing, heavy mouth bleeding that will not stop, serious facial or jaw injury, collapse, severe breathing difficulty or another emergency. If an oncology service has instructed the patient to treat sudden illness or infection symptoms as an emergency, follow that instruction. Do not wait for an overseas coordinator to reply.

SPS guidance for dentists caring for adults with cancer emphasises vigilance for dental infection and coordination with oncology or haematology during current or recent intensive treatment. The key principle is clinical ownership, not a copied waiting period. The exact treatment and current medical state determine the pathway.

Urgent assessment should identify whether there is an odontogenic infection, mucositis, fungal or viral lesion, medication-related ulceration, graft-versus-host disease, osteonecrosis, trauma or another condition. Similar symptoms can require different management. A photograph alone cannot establish the cause.

If a tooth can be stabilised or retained, that option should be considered. Extraction and immediate implant placement should not be presented as the automatic urgent solution. Once disease is controlled and the medical context is understood, elective replacement can be discussed without crisis pressure.

Immune, blood and healing context without website thresholds

Immune function is not represented by one label or one laboratory result. The dental clinician may need recent blood information, but the relevant tests, timing and interpretation depend on diagnosis, treatment phase and planned procedure. Oncology or haematology should advise when the patient is medically complex or current treatment affects infection, bleeding or healing.

Neutrophils, platelets, haemoglobin, lymphocyte subsets or immunoglobulins may be relevant in selected settings. This guide deliberately does not publish a pass-fail number. A value can change over time, different treatments produce different patterns, and a threshold without clinical context can be unsafe. The responsible medical team interprets results; the dentist uses that advice in the procedural plan.

Cancer and its treatment can affect infection defence, bleeding, oxygen delivery, nutrition, mucosal integrity and wound healing. The pattern varies. A patient with stable long-term surveillance is not equivalent to someone in an active cytotoxic phase, after transplant conditioning, with persistent cytopenia or on substantial immune suppression.

Ask about recent infections, hospital admissions, fever or sudden illness, bleeding or bruising, transfusions, poor intake, weight change, fatigue, wound problems and current precautions. These questions do not diagnose immune status. They help identify whether the oncology team should review the plan before elective surgery.

Blood-count interpretation should be tied to the proposed dental procedure. A non-invasive examination is different from raising a flap, preparing bone, grafting or operating at multiple sites. The dentist should describe the procedure accurately so the medical team can assess the relevant risk.

Do not assume an antimicrobial prescription makes an unsuitable surgical moment suitable. Preventive and therapeutic prescribing in immunocompromised patients can involve interactions, resistance, allergies, organ function and oncology protocols. The named dental prescriber and medical team should own the decision using current guidance.

Healing capacity also includes local biology. Periodontal inflammation, smoking, plaque, dry mouth, active infection, poor tissue quality and mechanical loading can matter. A normal-looking panoramic image does not establish soft-tissue health or immune readiness.

Oral mucosa, saliva and periodontal assessment

Cancer treatment can affect oral mucosa, salivary glands, taste, swallowing, nutrition, teeth, periodontium and prosthesis tolerance. The specific effects depend on treatment and patient. The examination should include more than implant bone volume.

Oral mucositis can involve painful erythema or ulceration during certain cancer therapies. MASCC/ISOO mucositis guidance is setting-specific and should be applied by the responsible clinical team. An elective implant plan should not ignore active mucosal disease, pain or difficulty maintaining oral care.

Dry mouth may follow head and neck radiotherapy or other cancer treatments and can increase practical difficulty with eating, speaking, dentures, caries prevention and hygiene. MASCC/ISOO and ASCO have separate guidance on salivary gland hypofunction and xerostomia. A website should not prescribe a universal rinse or saliva product. The oral-care professional should assess cause, remaining function, caries activity, mucosal condition and current oncology advice.

After allogeneic haematopoietic cell transplantation, chronic graft-versus-host disease can affect oral mucosa, salivary function and perioral tissues. The 2024 MASCC/ISOO clinical practice statement advises ongoing oral care and monitoring. Active lesions or significant functional problems need specialist assessment, not cosmetic implant scheduling from photographs.

Periodontal examination should record inflammation, pocketing, attachment, mobility, plaque control and prognosis of remaining teeth. Existing implants should be examined for peri-implant disease. MASCC/ISOO's haemato-oncology statement prioritises sources of infection and traumatic structures around cancer treatment, illustrating why oral diagnosis comes before elective replacement.

Assess decay, root condition, fractures, failing restorations, prostheses and sharp structures that may irritate vulnerable mucosa. Teeth should not be removed merely to simplify a full-arch plan. Ask whether each tooth is restorable and whether treatment burden is proportionate.

Imaging should answer a clinical question. A panoramic view may be part of assessment, but additional imaging must be justified. In post-radiotherapy planning, radiation records can be as important as dental imaging. A scan cannot reveal immune recovery or substitute for a treatment summary.

Oral hygiene advice should fit the patient's mucosal tolerance, dexterity and oncology instructions. A generic aggressive routine may be inappropriate when tissues are painful. The oncology or oral-care team should resolve any conflict between routine dental advice and a cancer-supportive-care protocol.

Head and neck radiotherapy boundary

Radiotherapy involving the jaws can create a lasting osteoradionecrosis concern after procedures that affect bone. The risk is not determined by the words radiation survivor alone. It depends on radiation dose distribution, the location of the planned implant or extraction, tissue and dental factors, time, other treatments and the proposed intervention.

The 2024 ISOO-MASCC-ASCO guideline on osteoradionecrosis says communication between the radiation oncologist and dental specialist is essential when invasive dental care is considered. Obtain the radiotherapy summary and, where needed, dose maps or site-specific information. Do not infer jaw exposure from the cancer's name.

The dental specialist should identify whether the planned site was in the treated volume and how that information affects alternatives. A blanket statement that one jaw region is suitable and another is not is unsafe. Dose and volume are spatial; the same patient can have different considerations at different sites.

Implant placement is not the only option. The guideline framework supports considering whether oral function can be restored without a bone-impacting procedure and whether the anticipated benefit justifies uncertainty. Options may include maintaining the current dentition, no replacement, a removable prosthesis or a tooth-supported solution where clinically reasonable.

Hyperbaric oxygen should not be sold as a standard implant add-on. The 2024 guideline evaluates preventive and management interventions and notes limits in evidence for several approaches. The specialist team should decide whether any adjunct is relevant. A clinic should disclose evidence uncertainty, burden, availability and cost without promising protection.

SPS advises referral to secondary dental care when oral or periodontal surgery is needed after head and neck radiotherapy. Local pathways vary, but the principle is that appropriately experienced teams should assess the irradiated site. An overseas general clinic should not claim equivalence without showing the actual responsible specialists and setting.

Consent should include osteoradionecrosis as relevant, the limits of prediction, alternatives, consequences of a complication, local follow-up and the travel implications of delayed healing. A generic consent form is not enough.

Antiresorptive and antiangiogenic medicine boundary

Some cancer patients receive antiresorptive medicines or antiangiogenic treatments associated with medication-related osteonecrosis of the jaw. The history must include current and past exposure, generic medicine, indication, route where relevant, dates, prescriber and any previous jaw symptoms or diagnosis.

SDCEP's MRONJ guidance was published in March 2017 and reviewed as extant in March 2024, with an updated supplement and cancer-patient information. It advises risk assessment and informed discussion for procedures that affect bone. A patient should not stop or delay a beneficial oncology medicine because a dental advertiser suggests a drug holiday.

The oncology indication matters. Cancer-related dosing and combinations may differ from treatment for a non-malignant bone condition. Do not assume the risk category from the word bisphosphonate or from whether a medicine is current. The named dentist should apply current guidance and seek specialist advice when appropriate.

Implant placement affects bone and therefore needs explicit consideration. Ask whether tooth retention, no replacement, a removable option or another non-surgical solution could avoid the procedure. If surgery remains under consideration, the patient should understand the uncertainty, potential for non-healing or exposed bone, escalation pathway and who will manage a problem.

Antibiotics or antiseptics should not be promoted as automatic prevention. The treating clinician should prescribe only for a clinical reason, after checking cancer treatment, interactions, allergies and current guidance. A package promise cannot remove MRONJ risk.

Antiangiogenic, targeted and immune therapies can also have oral effects or wound implications that differ by medicine. MASCC/ISOO published 2024 practice statements on oral complications of targeted therapy. The prescriber and dental clinician should identify the actual medicine rather than rely on the class label.

If the patient already has exposed bone, a non-healing site, pain, swelling, discharge, altered sensation or another concern, elective implant planning should stop and appropriate oral or maxillofacial assessment should occur. This guide does not diagnose MRONJ.

Implant-specific oral and functional assessment

Once medical and treatment boundaries are understood, implant assessment still requires ordinary dental fundamentals. The clinician should identify the reason for tooth loss, whether active disease is controlled, whether remaining teeth can be retained, periodontal status, bone and soft tissue, occlusion, hygiene capacity, smoking or nicotine exposure, restorative space and patient goals.

Cancer treatment may have changed anatomy, saliva, sensation, mouth opening, swallowing, manual ability or tolerance of appliances. Those functional factors influence whether implant treatment is the least burdensome option. A fixed full-arch concept should not be selected before this assessment.

Ask what function the patient wants to improve. Is the priority chewing, stability of a prosthesis, speech, comfort, appearance or reducing maintenance difficulty? Different goals can support different solutions. A removable option may be appropriate for one person and unmanageable for another.

If reconstructive surgery has changed jaw anatomy, involve an appropriately experienced restorative and surgical team. The plan may need prosthodontic, maxillofacial or speech-and-swallowing input. A standard travel-clinic workflow may not fit.

Implant maintenance must be realistic. Dry mouth, mucosal pain, restricted opening, fatigue or dexterity can make cleaning harder. Identify tools and professional support the patient can use without conflicting with oncology advice. The patient should know that implant placement creates a long-term maintenance obligation.

Remote photographs can support discussion but cannot measure periodontal health, assess mucosa fully, test teeth or interpret the cancer-treatment context. Any remote estimate should be labelled provisional and explain what can change after examination and specialist communication.

Staged assessment and alternatives

Staging separates urgent disease control from elective reconstruction. A reasonable sequence may include record collection, oncology or transplant input, oral examination, management of infection or mucosal disease, periodontal stabilisation, review, then a decision about replacement. This is a framework, not a fixed timeline.

If active cancer treatment is imminent, MASCC/ISOO's 2025 haemato-oncology statement prioritises oral problems likely to cause infection, pain, irritation or aspiration during treatment. That purpose is different from elective implant surgery. The dental and cancer teams should avoid delaying cancer care for a non-essential cosmetic plan.

Alternatives should be explicit:

• retain and restore a tooth where clinically reasonable;
• leave a space if function and stability permit;
• use a removable prosthesis;
• consider an adhesive or conventional bridge where appropriate;
• modify an existing prosthesis;
• defer replacement while health or treatment is changing;
• choose no implant treatment.

Each alternative has benefits, limits and maintenance. Avoid presenting implant surgery as the only modern solution. For a patient with irradiated bone, MRONJ-associated medicine, ongoing immune suppression or limited urgent access, a non-surgical option may materially change burden.

Staging can also limit surgical extent. One site or a less invasive phase may provide information before a larger plan, but it can add visits, cost and travel. The clinician should explain both sides and not imply that staging guarantees healing.

Second opinions are particularly useful when recommendations differ between dental, oncology and surgical teams. Share the same records so opinions address the same facts. A patient should not be penalised for asking for independent review.

Consent under uncertainty

Cancer-related implant decisions often contain genuine uncertainty. Valid consent requires the clinician to explain what is known, what is unknown and what could change the plan. GDC Principle 3 requires discussion of options, risks, benefits and possible costs, and documentation of continuing consent.

The written plan should name the clinic and clinicians, identify each site, state the diagnosis and goal, describe the proposed surgery, list alternatives, note relevant cancer-treatment factors, explain whether specialist input is outstanding, and outline aftercare. It should distinguish provisional remote information from an in-person clinical decision.

Risks should be procedure-specific. Depending on the case, discussion may include bleeding, infection, delayed healing, wound breakdown, osteoradionecrosis, medication-related osteonecrosis, implant non-integration, damage to nearby structures, mucosal problems, prosthetic complications and the need for additional care. This is not a prediction that every risk applies.

The patient should understand that oncology treatment takes priority when clinically necessary. A recurrence, new therapy, acute illness, medicine change or altered blood status may lead to postponement or cancellation. Deposit and refund terms should address that possibility before payment.

Do not use a fixed result percentage to reassure. Published studies combine different cancers, treatments, radiation exposure, medicines and follow-up. They cannot promise an individual's outcome. Ask the clinician what evidence supports the recommendation and whether it directly matches the case.

Consent includes the option to do nothing now. It also includes freedom to decline a changed plan after travel. A flight or short stay must not pressure a patient into extractions, grafting or a full-arch procedure that was not properly discussed.

Health data require privacy. Oncology letters, radiation maps, blood results and medicine lists should go to a verified clinic through a secure route. Ask who controls the data, why it is needed, who receives it, how long it is retained and how the patient can obtain a copy.

Records and clinical handover

GDC Principle 4 requires complete, accurate and contemporaneous records, including medical history, radiographs, consent, referrals and treatment discussions. Cross-border oncology-related care needs especially clear handover because several teams may share information without sharing a record system.

Before treatment, gather:

• exact diagnosis and current cancer status;
• treatment summaries and current oncology plan;
• radiotherapy field and dose-distribution information where relevant;
• transplant type, current precautions and graft-versus-host disease information where relevant;
• current and previous relevant medicines, including antiresorptive and antiangiogenic exposure;
• allergies and adverse reactions;
• recent blood information requested by the responsible clinician;
• oral and dental records, images and reports;
• contacts for oncology, haematology, transplant and usual dental teams.

The dental record should show which clinician reviewed each item, what questions were sent, what responses were received and how they changed the plan. A phrase such as medically cleared is not an adequate record.

After treatment, request the clinic's legal identity, treatment address, clinician names and registration, dated diagnosis, site-by-site procedure record, anaesthetic and medicine details, implant or device identifiers, graft or material information, images, aftercare, escalation route, review plan, invoice and complaint terms. A local clinician should be able to understand exactly what happened.

If a complication develops, the treating clinic should provide records promptly to the local dentist and oncology service. A coordinator may transmit documents with consent but cannot filter clinical information or tell the local professional how to treat.

Keep personal copies in a usable format. A screenshot may not preserve radiology metadata or laboratory context. Ask for original files and reports where available.

Infection warning signs and emergency boundary

Patients receiving anticancer treatment should follow the infection and emergency instructions supplied by their oncology or transplant service. NICE CG151 says suspected neutropenic sepsis is an acute medical emergency. It advises immediate assessment when a patient having anticancer treatment becomes unwell. Do not wait for a dental-tourism message.

Warning signs can include sudden illness, fever or temperature change according to the patient's oncology instructions, shivering, breathing difficulty, confusion, marked weakness, worsening mouth or facial swelling, spreading redness, pus, severe pain or inability to drink. Symptoms can vary, and severe infection may occur without a dramatic mouth appearance.

Call emergency services for breathing or swallowing difficulty, severe swelling of the mouth or neck, heavy bleeding that will not stop, collapse, serious facial injury or symptoms the oncology team has defined as an emergency. Contact the oncology advice line and secondary-care pathway as instructed.

Oral infection in a person with current immune suppression may require coordination between dental and medical teams. The dentist should not assume that a routine prescription is enough. Cultures, blood assessment, hospital care or another pathway may be needed; only the responsible clinicians can decide.

After implant surgery, the treating clinician should provide individual written expectations and escalation instructions. A generic online description cannot distinguish expected postoperative symptoms from infection, osteonecrosis, bleeding or another complication. Remote review has limits.

Mucosal ulceration, exposed bone, non-healing tissue, new altered sensation, increasing difficulty opening the mouth or persistent swallowing problems also deserve clinical assessment, especially after head and neck treatment or MRONJ-associated medicines. The urgency depends on symptoms and medical context.

Travel and the no-travel option

Travel separates the patient from oncology, usual dental care and familiar urgent pathways. That distance is part of clinical burden. A patient who needs frequent blood review, active cancer care, transplant precautions, complex wound management or specialist oral follow-up may be better served locally.

Before considering travel, verify the named clinic and named clinician, current registration, legal entity, treatment address, direct clinical contact, complaint route and aftercare. GDC guidance says a qualified dentist should assess the patient before a treatment plan and cost estimate. An event host or coordinator is not a substitute.

Ask whether the destination clinic can access the required specialist services. If a complication occurs, where will the patient go? Is there an established relationship with an oncology, haematology, oral medicine or maxillofacial service? Advertising words are not evidence; ask for named pathways.

Fitness to travel is a medical question for the usual-care team and travel provider. A coordinator cannot decide it. Consider current infection risk, mobility, fatigue, nutrition, medicine storage, time zones, access to care, insurance exclusions and the possibility that the cancer plan changes.

Travel insurance may exclude planned treatment, existing cancer, complications or additional stays. Ask the insurer directly and retain the answer. The clinic cannot promise reimbursement.

The return journey should not be scheduled before the treating clinician's necessary review. This guide does not set a fixed interval. Ask what clinical findings are required, what would delay departure and who pays for changed transport or accommodation.

Travel logistics must be confirmed in writing and kept separate from clinical consent. No transport, hotel, companion, translation or extra clinical care should be inferred from generic marketing.

The no-travel option should remain visible. Local treatment may simplify specialist communication, urgent access and long-term maintenance. A hybrid plan may use local disease control and specialist assessment before any later elective decision. Choosing local care or no implant is a legitimate result.

Local aftercare and escalation

Arrange local dental aftercare before overseas surgery. Ask a local dentist or hospital dental service whether it can provide the anticipated review. Do not assume another clinician must accept responsibility for a procedure performed elsewhere.

The treating clinician should provide site-specific wound instructions, medicine records, expected symptoms, urgent signs and direct clinical contact. These instructions must align with oncology or transplant precautions. If there is a conflict, the clinicians should resolve it directly.

Remote review can help share symptoms and images but cannot palpate tissues, assess vital signs, take blood, obtain cultures or produce diagnostic imaging. A video call should not be marketed as universal emergency care.

Long-term maintenance includes periodontal monitoring, plaque control, implant and prosthesis review, and management of dry mouth or mucosal disease. The frequency and method should be individual. Active graft-versus-host disease, salivary hypofunction or limited mouth opening may need an oral medicine or special care pathway.

Cancer surveillance continues independently of implant care. A new oral lesion, unexplained non-healing area or other concern should be evaluated through the appropriate pathway, not attributed automatically to an implant.

Complaint and remedial terms should be read before payment. Clarify what evidence is needed, whether return to the original clinic is required, what local care is covered, which travel costs are excluded and what independent complaint route applies. A headline assurance does not answer those questions.

Questions to ask before implant treatment

Cancer and medical status

• What exact diagnosis and current treatment status have you recorded?
• Which surgery, systemic therapy, radiotherapy, transplant or cellular therapy is relevant?
• Which current and previous medicines could affect immune, blood, bone or oral tissues?
• Who is the named oncology, haematology or transplant contact?
• What focused questions will the dental clinician ask that team?
• Which recent blood or medical information is needed, and who will interpret it?
• Is graft-versus-host disease, dry mouth, mucositis or another oral effect active?

Radiation and medicine boundaries

• Did radiotherapy involve the jaw site planned for surgery?
• Has the dental specialist reviewed dose-distribution information?
• Is secondary-care oral or maxillofacial review needed?
• Have antiresorptive or antiangiogenic medicines been recorded, including previous exposure?
• How does current SDCEP guidance affect the options?
• Is exposed bone or a non-healing site already present?

Dental plan and alternatives

• What diagnosis supports removal or replacement of each tooth?
• Can a tooth be retained?
• What no-surgery and no-treatment alternatives are reasonable?
• What periodontal and mucosal findings matter?
• What is the anticipated surgical extent?
• Could grafting or another procedure be added?
• Can care be staged or provided locally?

Consent, records and aftercare

• Who is the named clinician responsible for surgery and consent?
• What is known and uncertain about infection, bleeding, healing and osteonecrosis?
• What could cause postponement or cancellation?
• What records and device identifiers will I receive?
• Who provides local review and emergency care?
• What can remote review not assess?
• What are the itemised costs, cancellation and complaint terms?
• Are travel services separate and confirmed in writing?

Cancer-survivor implant planning checklist

Before the first dental decision

• Write down the oral symptom, functional goal and anything urgent.
• Obtain the exact diagnosis and current status from oncology records.
• List every treatment modality and relevant date or treatment phase.
• Obtain radiotherapy field and dose information if the head or neck was treated.
• List all current and relevant previous medicines using generic names where possible.
• Include transplant, CAR T-cell and graft-versus-host disease information where relevant.
• Identify the named oncology, haematology or transplant contact.
• Gather dental records and images.
• Verify the clinic, clinician and secure data route.

Before accepting implant surgery

• Obtain a current oral, periodontal and mucosal assessment.
• Ask whether active infection or disease should be treated first.
• Confirm the dental clinician has reviewed relevant medical information.
• Ensure specialist questions and answers are documented.
• Compare tooth retention, removable, bridge, no-replacement and no-treatment options.
• Review radiotherapy and MRONJ boundaries where relevant.
• Ask what remains provisional.
• Obtain a site-by-site written plan, risks, alternatives and itemised costs.
• Review privacy, cancellation, complaint and remedial terms.
• Arrange local aftercare.

Before travel

• Confirm there has been no treatment, medicine or health-status change.
• Follow the usual oncology or transplant team's travel and infection advice.
• Carry medicines and alert information as instructed by the prescriber.
• Confirm clinic address and direct clinical contact.
• Confirm travel logistics in writing.
• Check insurance directly.
• Identify urgent dental, oncology and emergency pathways at the destination.
• Keep a contingency for postponed treatment or delayed return.

Before discharge

• Receive the final procedure and medicine record.
• Obtain implant or device identifiers, material information and images.
• Receive individual aftercare and infection-escalation instructions.
• Confirm the necessary review before travel.
• Confirm how the local dentist and oncology service can contact the treating clinician.
• Check the invoice and complaint route.

After returning home

• Follow the written plans from dental and oncology teams.
• Do not self-adjust cancer or immune medicines.
• Use the oncology emergency pathway if instructed or suddenly unwell.
• Use local urgent dental care for worsening oral symptoms.
• Attend agreed maintenance and specialist review.
• Keep records of symptoms, advice, examinations and costs.

Sources and review dates

Guidance changes as cancer therapies and supportive care evolve. The named dental and oncology professionals should consult current versions for the individual patient. This guide used:

• MASCC/ISOO Clinical Practice Statement, dental evaluation and management prior to treatment for haematological malignancies and CAR T-cell therapy, published 13 September 2025: coordinated assessment, infection priorities, blood and immune context, and treatment-phase ownership. https://pubmed.ncbi.nlm.nih.gov/40944758/
• ISOO-MASCC-ASCO guideline, Prevention and Management of Osteoradionecrosis in Patients With Head and Neck Cancer Treated With Radiation Therapy, published 2024: site-specific radiation assessment, communication and alternatives. https://ascopubs.org/doi/10.1200/JCO.23.02750
• SDCEP MRONJ guidance, published March 2017 and reviewed as extant March 2024: antiresorptive and antiangiogenic medicine risk assessment, prevention, consent and specialist advice. https://www.sdcep.org.uk/published-guidance/medication-related-osteonecrosis-of-the-jaw/
• SPS, How should adults with cancer be managed by general dental practitioners if they need dental treatment?, updated 13 April 2026: oncology or haematology liaison, infection, treatment setting, radiotherapy and MRONJ considerations. https://www.sps.nhs.uk/articles/how-should-adults-with-cancer-be-managed-by-general-dental-practitioners-if-they-need-dental-treatment/
• NICE CG151, Neutropenic sepsis: prevention and management in people with cancer, updated September 2024 and accessed 29 August 2026: sudden illness during anticancer treatment and emergency secondary-care assessment. https://www.nice.org.uk/guidance/cg151/chapter/recommendations
• MASCC/ISOO Clinical Practice Statement, Management of oral manifestations of chronic graft-versus-host disease, published 25 July 2024: oral mucosa, salivary function, secondary infection and monitoring. https://pubmed.ncbi.nlm.nih.gov/39048807/
• MASCC/ISOO clinical practice guidelines for mucositis secondary to cancer therapy, published 2020 and accessed 29 August 2026: setting-specific oral mucositis care. https://pubmed.ncbi.nlm.nih.gov/32786044/
• ISOO/MASCC/ASCO guideline on salivary gland hypofunction and xerostomia induced by nonsurgical cancer therapies, published 2021 and accessed 29 August 2026. https://pubmed.ncbi.nlm.nih.gov/34283635/
• GDC Principle 3, Obtain valid consent, accessed 29 August 2026: options, risks, benefits, costs and continuing consent. https://standards.gdc-uk.org/pages/principle3/principle3
• GDC Principle 4, Maintain and protect patients' information, accessed 29 August 2026: accurate medical and dental records, confidentiality and handover. https://standards.gdc-uk.org/pages/principle4/principle4
• GDC, Going abroad for dental treatment, accessed 29 August 2026: qualified assessment, provider verification, aftercare and complaint planning. https://www.gdc-uk.org/standards-guidance/information-for-patients-public/going-abroad-for-dental-treatment
• NHS urgent dental guidance, accessed 29 August 2026: urgent dental access and emergency boundaries. https://www.nhs.uk/nhs-services/dentists/how-to-find-an-nhs-dentist-in-an-emergency/

Evidence supports careful coordination, not blanket eligibility. The decision belongs to the patient, the named dental clinician and the oncology, haematology or transplant professionals who understand the current diagnosis and treatment.